
Release date: 2024-08-15 14:54:29 Article From: Lucius Laos Recommended: 384
The core mechanism of Pemigatinib, a class of small molecule kinase blockers specifically targeting FGFR1, FGFR2, and FGFR3 receptors, lies in the effective inhibition of phosphorylation activity on these receptors and the subsequent development of complex signaling pathways.
Pemigatinib is a targeted drug that may interact with a variety of drugs during treatment.
Some drugs, such as crizotinib and ketoconazole, may inhibit the activity of the CYP3A4 enzyme, resulting in a slowdown in the metabolism of Pemigatinib in the body and an increase in blood concentration, thereby increasing the risk of toxic side effects.
Some drugs, such as ribavirin and erythromycin, may induce the activity of the CYP3A4 enzyme, accelerate the metabolism of Pemigatinib, reduce its blood concentration, and affect the therapeutic effect.
Measures to deal with drug interactions mainly include the following:
In the case of guaranteed efficacy, the number of drugs used in combination should be minimized to reduce the risk of drug interactions.
Physicians should make full use of computerized drug interaction warning systems, which can assist physicians in reviewing patients' drug regimens and predicting and preventing adverse drug interactions and adverse reactions.
When using Pemigatinib, patients and their families need to pay attention to the following aspects to ensure safe and effective treatment.
Although OCT is not routinely performed in clinical trials to detect asymptomatic RPED, patients should still have regular eye examinations, especially those with a history of ocular disease or high-risk factors. This helps to detect and treat any potential eye problems early.
Pemigatinib may have an effect on liver function, so regular monitoring of liver function parameters is required during use. If a person's liver function is abnormal, doctors may need to adjust the dose or take other measures.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended:[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended:[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended:[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended:[list:visits]2026-16-07
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease pa···【more】
Recommended:[list:visits]2026-15-07
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulat···【more】
Recommended:[list:visits]2026-14-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643